Elevance Health, Inc. (NYSE:ELV – Get Free Report) reached a new 52-week high during trading on Thursday after Mizuho raised their price target on the stock from $575.00 to $585.00. Mizuho currently has a buy rating on the stock. Elevance Health traded as high as $539.95 and last traded at $539.47, with a volume of 206072 shares changing hands. The stock had previously closed at $533.73.
Several other equities research analysts also recently commented on ELV. UBS Group increased their price objective on Elevance Health from $585.00 to $605.00 and gave the company a “buy” rating in a report on Friday, April 19th. Royal Bank of Canada raised their price target on Elevance Health from $574.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, April 19th. StockNews.com downgraded Elevance Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 25th. Wells Fargo & Company raised their price target on Elevance Health from $557.00 to $600.00 and gave the company an “overweight” rating in a report on Friday, April 19th. Finally, Truist Financial reaffirmed a “buy” rating and set a $600.00 price target (up previously from $580.00) on shares of Elevance Health in a report on Friday, April 19th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $587.42.
Get Our Latest Analysis on Elevance Health
Insiders Place Their Bets
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of ELV. Sanders Capital LLC boosted its stake in Elevance Health by 4.6% in the fourth quarter. Sanders Capital LLC now owns 4,457,986 shares of the company’s stock valued at $2,102,208,000 after buying an additional 196,010 shares in the last quarter. Capital International Investors boosted its stake in Elevance Health by 7.9% in the fourth quarter. Capital International Investors now owns 3,374,709 shares of the company’s stock valued at $1,591,237,000 after buying an additional 248,150 shares in the last quarter. Baillie Gifford & Co. boosted its stake in Elevance Health by 0.9% in the fourth quarter. Baillie Gifford & Co. now owns 3,087,904 shares of the company’s stock valued at $1,456,132,000 after buying an additional 27,986 shares in the last quarter. Norges Bank acquired a new stake in Elevance Health in the fourth quarter valued at about $1,347,434,000. Finally, Morgan Stanley boosted its stake in Elevance Health by 1.7% in the third quarter. Morgan Stanley now owns 2,784,714 shares of the company’s stock valued at $1,212,521,000 after buying an additional 46,322 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.
Elevance Health Stock Down 0.4 %
The firm has a 50 day moving average of $511.89 and a two-hundred day moving average of $486.40. The firm has a market capitalization of $124.87 billion, a price-to-earnings ratio of 20.30, a price-to-earnings-growth ratio of 1.18 and a beta of 0.78. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.54.
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings results on Thursday, April 18th. The company reported $10.64 EPS for the quarter, beating analysts’ consensus estimates of $10.54 by $0.10. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The firm had revenue of $42.27 billion for the quarter, compared to analyst estimates of $42.49 billion. During the same period last year, the firm posted $9.46 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 37.24 EPS for the current fiscal year.
Elevance Health Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Stockholders of record on Monday, June 10th will be paid a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date is Monday, June 10th. Elevance Health’s payout ratio is 24.64%.
About Elevance Health
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
See Also
- Five stocks we like better than Elevance Health
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Stocks Leading the U.S. Agriculture Comeback
- How Can Investors Benefit From After-Hours Trading
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is the Dow Jones Industrial Average (DJIA)?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.